In June 2020 it was announced that J&J would buy Momenta Pharmaceuticals (NASDAQ:MNTA) for $6.5B. Originally based on technology developed at, and licensed from, Massachusetts Institute of Technology (MIT), Momenta Pharmaceuticals, Inc. - initially doing business as Mineion, Inc., is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, novel drugs, and the discovery of new biological processes. SBIR-involved on a very limited basis in its early years, based on the firm's understanding of sugars Momenta has developed a diversified pipeline of novel discovery and development candidates and near-term product opportunities. By enabling detailed chemical and structural analysis of complex sugars, the firm's technology provides a more complete understanding of the roles that sugars play in cellular function, disease, and drug action.
